| 3.3 -0.5 (-13.16%) | 06-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.7 | 1-year : | 5.49 |
| Resists | First : | 4.02 | Second : | 4.7 |
| Pivot price | 2.98  |
|||
| Supports | First : | 3.01 | Second : | 2.39 |
| MAs | MA(5) : | 3.52 |
MA(20) : | 2.94 |
| MA(100) : | 4.53 |
MA(250) : | 5.33 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 78.1 |
D(3) : | 86.2 |
| RSI | RSI(14): 53.5 |
|||
| 52-week | High : | 8.77 | Low : | 2.39 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ QTRX ] has closed below upper band by 31.2%. Bollinger Bands are 22.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.84 - 3.86 | 3.86 - 3.88 |
| Low: | 3.23 - 3.25 | 3.25 - 3.27 |
| Close: | 3.27 - 3.3 | 3.3 - 3.33 |
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Sat, 06 Jun 2026
Quanterix Q1 2026 slides: $85M synergies offset organic decline - Investing.com
Thu, 04 Jun 2026
Earnings call transcript: Quanterix Q1 2026 EPS beats, revenue misses - Investing.com
Thu, 04 Jun 2026
Quanterix Corporation Appoints Geoff Albrecht as Senior Vice President and General Manager of Diagnostics - marketscreener.com
Thu, 04 Jun 2026
Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics - Quantisnow
Wed, 03 Jun 2026
Quanterix to Take Part in Conference - Baystreet.ca
Wed, 03 Jun 2026
Quanterix CEO to host June 9 fireside chat at Goldman Sachs healthcare event - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 47 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 6.2 (%) |
| Held by Institutions | 85.4 (%) |
| Shares Short | 5,150 (K) |
| Shares Short P.Month | 4,300 (K) |
| EPS | -2.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.98 |
| Profit Margin | -71.9 % |
| Operating Margin | -59.2 % |
| Return on Assets (ttm) | -13.4 % |
| Return on Equity (ttm) | -34.9 % |
| Qtrly Rev. Growth | 20.1 % |
| Gross Profit (p.s.) | 1.39 |
| Sales Per Share | 3.07 |
| EBITDA (p.s.) | -1.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -81 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -1.41 |
| PEG Ratio | 0 |
| Price to Book value | 0.55 |
| Price to Sales | 1.07 |
| Price to Cash Flow | -1.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|